By Amber Deter The Compass Therapeutics IPO is set to hit the market. The company saw successful preclinical trials and hopes to have its products approved by 2022. Now, investors are interested in Compass Therapeutics stock.
But is Compass Therapeutics a good investment? Here’s what we know…
Compass Therapeutics IPO: The Business
Thomas Schuetz, MD, PhD co-founded Compass Therapeutics in 2014. At the time, he was a venture partner at OrbiMed, Compass’ largest shareholder. The company is a clinical-stage biopharmaceutical company. Compass’ goal is to support the role of the immune system using anti-body based therapies to fight cancer. It claims its approach can be used …read more
